Renaissance Technologies’s DiaMedica Therapeutics DMAC Stock Holding History

Renaissance Technologies’s Portfolio DMAC Stock Details DMAC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$356K	Buy	+52,523	New	+$416K	﹤0.01%	2746
2023 Q2	–	Sell	-64,508	Closed	-$99K	–	3995
2023 Q1	$99K	Buy	64,508 +30,889	+92%	+$49K	﹤0.01%	3495
2022 Q4	$53K	Buy	+33,619	New	+$45.3K	﹤0.01%	3786
2021 Q3	–	Sell	-94,100	Closed	-$419K	–	3540
2021 Q2	$419K	Sell	94,100 -59,000	-39%	-$484K	﹤0.01%	3031
2021 Q1	$1.4M	Buy	153,100 +39,700	+35%	+$371K	﹤0.01%	2436
2020 Q4	$1.15M	Buy	113,400 +17,400	+18%	+$95.2K	﹤0.01%	2428
2020 Q3	$407K	Sell	96,000 -8,700	-8%	-$46K	﹤0.01%	2893
2020 Q2	$726K	Buy	104,700 +78,851	+305%	+$352K	﹤0.01%	2710
2020 Q1	$72K	Buy	+25,849	New	+$107K	﹤0.01%	3281

Other funds holding DMAC

CLG

Cooperman Leon G $3.05B AUM 42.78% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

PAPAIJV

Paragon Associates & Paragon Associates II Joint Venture Dallas, Texas $73.6M AUM 61.93% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return

Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Renaissance Technologies's DMAC Position: Q1 2026 in Review

Renaissance Technologies opened a new position in DiaMedica Therapeutics (DMAC) in Q1 2026: 52,523 shares worth $356K. The stake represents ﹤0.01% of the portfolio and ranks #2746 among its holdings. This is a return to the name: Renaissance Technologies previously reported a position in DMAC as recently as Q1 2023.

Renaissance Technologies first reported a position in DMAC in Q1 2020 and has held it in 9 quarters since. The position peaked at $1.4M in Q1 2021. 98 funds tracked by Wall St. Rank hold DMAC as of Q1 2026.

Renaissance Technologies held 52,523 shares of DiaMedica Therapeutics worth $356K as of Q1 2026.
DiaMedica Therapeutics was a new Renaissance Technologies position in Q1 2026.
DiaMedica Therapeutics made up ﹤0.01% of Renaissance Technologies's portfolio in Q1 2026, its #2746 holding.
Renaissance Technologies first reported a position in DiaMedica Therapeutics in Q1 2020 and has held it in 9 quarters since.
Renaissance Technologies's DiaMedica Therapeutics position peaked at $1.4M in Q1 2021.
98 funds tracked by Wall St. Rank held DiaMedica Therapeutics as of Q1 2026.

Based on Renaissance Technologies's 13F filing for Q1 2026, filed 14 May 2026.